UNH Research Update — April 22, 2026
Updated Thesis
UnitedHealth Group Incorporated operates as a leading healthcare company with two main platforms: UnitedHealthcare, providing health benefits coverage, and Optum, offering information and technology services. The company benefits from a durable competitive moat due to its scale, integrated platforms, and broad market reach serving over 170 million consumers. Despite strong revenue growth of 12% year-over-year in 2025 to $447.6 billion, earnings have been pressured by Medicare funding cuts, Inflation Reduction Act impacts, and elevated medical costs, resulting in a net margin of 2.7% and a 41% decline in full-year earnings to $19 billion.
The investment grade as of this refresh is B — solid business quality. High-tier business, mid-tier valuation
Key Metrics at a Glance
- Revenue growth: +2.0% year over year
- Net margin: 2.7%
- Forward P/E: 26.7x
- Fair value upside: +97.1% to our estimate of $697
Current price: $353.52
These figures reflect our most recent data pull and are one input into a multi-factor valuation framework.
Our 12–18 Month Outlook
Quality companies held over a multi-year horizon benefit from compounding fundamentals and the patience to ride through short-term volatility. UnitedHealth Group Incorporated remains in our covered universe with a solid-quality assessment. We update research when material data changes — earnings revisions, management shifts, or regime changes in valuation — not on every price fluctuation.
Long-term accumulation of quality businesses at fair or better prices is the core of the Patient Accumulator approach. Research updates like this one inform whether to add, hold, or wait for a better zone — not whether to react to short-term price moves.
[View full UNH research →](/stocks/UNH)